Zeo ScientifiX (ZEOX) Research & Development (2025 - 2026)
Zeo ScientifiX (ZEOX) posted quarterly Research & Development of $31000.0 for Q2 2026, down 26.19% year-over-year from $42000.0 in Q2 2025, and up 63.16% quarter-over-quarter from $19000.0 in Q1 2026.
Zeo ScientifiX (ZEOX) Research & Development (2025 - 2026) Analysis & Trends
Zeo ScientifiX's Research & Development history runs 2 years deep, the most recent figure standing at $31000.0 for Q2 2026.
- In Q2 2026, Research & Development fell 26.19% year-over-year to $31000.0; the TTM figure through Apr 2026 stood at $98000.0 (changed N/A YoY), while the FY2025 annual figure was $100000.0, down 39.02% from the prior year.
- Research & Development for Q2 2026 stood at $31000.0, up from $19000.0 in the prior quarter.
- The five-year high for Research & Development was $42000.0 in Q2 2025, with the low at $6000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Zeo ScientifiX | 11.02 Mn | 9.17 Mn | 2.06 Mn | 31,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 31,000.00 |
| Jan 31, 2026 | 19,000.00 |
| Apr 30, 2025 | 42,000.00 |
| Jan 31, 2025 | 6,000.00 |